Skip to main content

Table 1 Phenotypic parameters of Lean and Obese Zucker rats at the end of the 10 treatment period

From: The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat

Parameter (n) ZLC (6) ZOC (7–13) ZOSV (7–13) ZOV (7–13) ZOH (7–14)
Body weight (g) 472 ± 17 752 ± 17*§ 709 ± 27* 733 ± 16* 657 ± 28*
Left kidney weight/TL (mg/mm) 28.7 ± 0.8 52.9 ± 1.8a 54.6 ± 3.9* 52.3 ± 2.1 65.9 ± 9.6*
Epididymal fat (g) 7.4 ± 0.9 20.6 ± 1.5* 17.9 ± 1.3* 21.1 ± 1.2* 16.6 ± 1.4*
Retroperitoneal fat (g) 7.2 ± 0.8 46.6 ± 2.8* 48.0 ± 3.4* 50.4 ± 3.6*§ 36.6 ± 2.7*
Blood parameters
 HbA1c (%) 3.7 ± 0.1 5.0 ± 0.5 4.4 ± 0.3 5.5 ± 0.5a 4.6 ± 0.4
 Fasting glucose (mg dL−1) (mmol L−1) 100 ± 5 148 ± 7a 169 ± 25 184 ± 17a 174 ± 25
 Fasting insulin mU L−1 25.7 ± 10 109 ± 19* 113 ± 32* 105 ± 15* 119 ± 23*
 HOMA-IR (FG FI)/405 7 ± 3 42 ± 10* 45 ± 9* 53 ± 11* 45 ± 11*
 Cholesterol (mg dL−1) 100 ± 11 468 ± 66* 265 ± 30†§ 308 ± 35* 407 ± 69*
 Triglycerides (mg dL−1) 84 ± 12 2000 ± 394* 1348 ± 307* 1259 ± 214* 2550 ± 719*
 Creatinine (mg dL−1) 0.32 ± 0.02 0.45 ± 0.09 0.29 ± 0.04 0.33 ± 0.04 0.44 ± 0.13
 AspAT (U L−1) 78 ± 14 240 ± 61 202 ± 43 248 ± 59 127 ± 22
 AlaAT (U L−1) 40 ± 5 139 ± 33* 132 ± 30 161 ± 30* 73 ± 12
 Sodium (mEq L−1) 138 ± 1 133 ± 2 135 ± 1 134 ± 1 127 ± 4
  1. ZOC, ZO control; ZOSV, ZO treated with Sac/val; ZOV, ZO treated with valsartan; ZOH, ZO treated with hydralazine; TL, tibia length; HOMA-IR, homeostatic model assessment of insulin resistance; AspAT, aspartate aminotransferase; AlaAT, alanine aminotransferase
  2. Values are mean ± SE and sample sizes are shown in parentheses. ANOVA post hoc comparisons: * P < 0.05 vs ZLC;  P < 0.05 versus ZOC; § P < 0.05 versus ZOH. Two-tailed t-tests: a P < 0.05 versus ZLC; b P < 0.05 versus ZOC